MedTech Terms
    The authoritative reference
    Sign in
    Methodology

    How MedTech Terms are researched, reviewed, and kept current

    A short, public account of the editorial process behind every entry. Written so readers, regulators, and AI-citation engines can judge the reliability of the content.

    1. Term selection

    Terms are chosen from primary regulatory frameworks (FDA CFR and guidance, EU MDR/IVDR, ISO, IEC, IMDRF), from standard industry vocabularies (MDCG, HL7, DICOM, NEMA), and from questions submitted by readers. We add a term when it appears in a rule or guidance document and is likely to be misunderstood or conflated with another term.

    2. Sourcing

    Every entry is written from primary sources: the FD&C Act, 21 CFR, EU regulations and MDCG guidance, ISO/IEC standards, IMDRF documents, CISA advisories, and NIST publications. We cite the source directly on the term page. Secondary sources (trade press, vendor blogs) are used to identify a topic but never to define it.

    3. Drafting

    A draft has five sections: plain-English definition, what the regulation says, what it means in practice, common pitfalls or FAQs, and related terms. We write for engineers, regulatory affairs, and quality professionals. We avoid marketing language and vendor-specific framing.

    4. Editorial review

    Christian Espinosa, Founder of Blue Goat Cyber, reviews each term for regulatory and technical accuracy. Cybersecurity terms receive extra scrutiny given his focus area. The review date is stamped on every page in the byline and in the DefinedTerm JSON-LD (dateModified).

    5. Citations and cross-links

    Every term links to its primary sources with source, publisher, and label. Definitions cross-link to related terms so the glossary functions as a connected graph, not a list. Comparison pages sit alongside term pages when two concepts are frequently confused (for example 510(k) vs PMA, SaMD vs SiMD).

    6. Ongoing updates

    Terms are re-reviewed when a cited regulation changes (for example the QSR to QMSR transition, MDR/IVDR transition extensions, or new FDA guidance). The Latest feed ingests regulator publications daily so newly-affected terms surface quickly. Corrections and reader questions are welcome.

    Citations

    Source-tier hierarchy

    Not every source carries equal weight. We rank citations into five tiers so readers can see, at a glance, whether a claim is grounded in binding law, regulator guidance, peer-reviewed evidence, industry commentary, or vendor material. Definitions are drawn from Tier 1 and Tier 2 wherever possible; Tier 5 is never cited.

    1. Tier 1

      Binding law and regulation

      Definitional

      The text of statutes, regulations, and directly-referenced standards. Used to define terms and to state what a rule requires.

      • US: FD&C Act, 21 CFR Parts 800-1299, 21 CFR Part 11
      • EU: MDR 2017/745, IVDR 2017/746, EU AI Act
      • Standards incorporated by reference (for example ISO 13485, ISO 14971, IEC 62304, IEC 62366-1)
    2. Tier 2

      Regulator guidance and consensus documents

      Authoritative interpretation

      How regulators and international bodies interpret and apply the law. Used for practice detail, thresholds, and scope clarifications.

      • FDA guidance documents, Q-Sub program materials, openFDA data
      • EU MDCG guidance, EMA scientific guidelines, notified body position papers
      • IMDRF, IEEE, HL7, DICOM, NEMA, AAMI, NIST, CISA advisories
    3. Tier 3

      Peer-reviewed and primary research

      Supporting evidence

      Peer-reviewed literature and registered clinical evidence. Used to support what happens in practice, not to define a regulatory term.

      • PubMed / NIH-indexed journals
      • ClinicalTrials.gov registered interventional studies
      • Health-technology assessments from HTA bodies (NICE, CADTH, IQWiG)
    4. Tier 4

      Trade press and expert commentary

      Context only

      Used to identify a topic worth covering or to note how the industry is reacting. Never used to define a term or to make a regulatory claim.

      • Established regulatory and MedTech trade publications
      • Recognized subject-matter blogs from regulatory attorneys and consultants
      • Conference proceedings and standards-body workshops
    5. Tier 5

      Vendor and community sources

      Not cited

      Vendor marketing, product pages, unverified forum posts, and undated PDFs are not used as citations. They may point us to a term but they do not appear in the reference list.

      • Vendor product pages, whitepapers, and pitch decks
      • Anonymous forum threads and social media posts
      • Undated or unattributed PDFs

    Each term page lists its primary references with source, publisher, and label. If a citation moves between tiers (for example when a guidance document is superseded), the term is re-reviewed and the review date is updated.

    Editorial principles

    • Vendor-neutral. We do not name specific products, companies, or investors. Investing and finance terminology is in scope; brand placement is not.
    • Primary sources over commentary. If a claim cannot be tied back to a regulation, standard, or guidance document, we do not make it.
    • Editorially independent. Blue Goat Cyber sponsors the site. It does not shape which terms are covered or how they are defined.
    • Educational, not advisory. Content supports decisions; it does not replace qualified regulatory, legal, or clinical counsel.
    • Corrections in the open. If a term is wrong, we fix it, stamp a new review date, and note substantive changes.

    Editorial reviewer

    Christian Espinosa, Founder and CEO of Blue Goat Cyber, is the editorial reviewer. His byline appears on every term page with the date of last review.

    About Christian Espinosa
    Corrections and suggestions. Spotted an error, a stale citation, or a term that belongs in the glossary? Send it via the Blue Goat Cyber contact channels; substantive changes are stamped with a new review date.